Sen, Zümrüt Duygu
Chand, Tara
Danyeli, Lena Vera
Kumar, Vinod Jangir
Colic, Lejla
Li, Meng
Yemisken, Merve
Javaheripour, Nooshin
Refisch, Alexander
Opel, Nils
Macharadze, Tamar
Kretzschmar, Moritz
Ozkan, Esra
Deliano, Matthias
Walter, Martin
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SFB779/A06)
Universitätsklinikum Jena
Article History
Received: 15 February 2023
Accepted: 4 August 2023
First Online: 16 August 2023
Change Date: 22 September 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41598-023-42343-3
Competing interests
: MW is a member of the following advisory boards and gave presentations to the following companies: Bayer AG, Germany; Boehringer Ingelheim, Germany; and Biologische Heilmittel Heel GmbH, Germany. MW has further conducted studies with institutional research support from HEEL and Janssen Pharmaceutical Research for a clinical trial (IIT) on ketamine in patients with MDD, unrelated to this investigation. MW did not receive any financial compensation from the companies mentioned above. All other authors report no biomedical financial interests or other potential conflicts of interest.